Louapre, C. http://orcid.org/0000-0002-4987-1531
Rosenzwajg, M. http://orcid.org/0000-0001-5312-6203
Golse, M.
Roux, A.
Pitoiset, F.
Adda, L.
Tchitchek, N.
Papeix, C.
Maillart, E.
Ungureanu, A.
Charbonnier-Beaupel, F.
Galanaud, D.
Corvol, J. C.
Vicaut, E.
Lubetzki, C.
Klatzmann, D. http://orcid.org/0000-0002-0054-3422
Clinical trials referenced in this document:
Documents that mention this clinical trial
A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing–remitting multiple sclerosis
https://doi.org/10.1007/s00415-023-11690-6
Funding for this research was provided by:
Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques
ANR (ANR-16-RHUS-0001)
Article History
Received: 13 February 2023
Revised: 24 March 2023
Accepted: 26 March 2023
First Online: 28 May 2023
Declarations
:
: DK and MR are inventors of a patent application owned by their institutions that protects the use of low-dose IL2 in autoimmune diseases. This patent has been licensed to ILTOO pharma in which they hold shares.
: The study was approved by the institutional review board of Pitié-Salpêtrière Hospital (CPP Ile de France VI) and was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. The study protocol is registered on ClinicalTrials.gov (NCT02424396). Written, informed consent was obtained from all participants before enrolment in the study.
: The study was approved by the institutional review board of Pitié-Salpêtrière Hospital (CPP Ile de France VI) and was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. The study protocol is registered on ClinicalTrials.gov (NCT02424396).
: Written, informed consent was obtained from all participants before enrolment in the study.